GlassScriptPhysician profile
Franklin Goldwire
NPI 1124227012
$1,616.84
in general payments reported to CMS, 2019-2025
14 companies · $59.35 in 2025
The $59.35 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $11.41 · 2021: $87.50 · 2022: $679 · 2023: $469 · 2024: $209 · 2025: $59.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $388.82 | 2019-2025 | Endoclot Phs, Hanarostent Lowaxtm Duodenum/Pylorus(Nnn), Visiglide |
| Abbvie INC. | $314.60 | 2023-2024 | |
| Boston Scientific Corporation | $295.65 | 2020-2022 | |
| Redhill Biopharma INC. | $112.12 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.16 | 2022 | |
| Medtronic, INC. | $100.03 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.51 | 2023-2024 | Xifaxan |
| Janssen Biotech, INC. | $74.13 | 2023-2025 | Stelara, Tremfya, Remicade |
| Endogastric Solutions, INC | $40.50 | 2024 | Esophyx |
| Aimmune Therapeutics, INC. | $22.57 | 2024 | |
| Gilead Sciences, INC. | $18.67 | 2025 | |
| Evoke Pharma, INC. | $17.02 | 2023 | Gimoti |
| Ferring Pharmaceuticals INC. | $16.87 | 2023 | Rebyota |
| Ardelyx, INC. | $16.19 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franklin Goldwire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.